Note sull'episodio
In 2017 two respected Danish Scientists claimed that higher dosages of the GLP1 Semaglutide, which had been planned as a treatment for Obesity, were not supported by the Clinical trials. I look at the timing of this article and their controversial statement. I search for the missing Phase II Ozempic Clinical trials and take a look at the Phase III Ozempic Trials on Diabetics and question the small amount of weight loss found alongside the large number of side effects. I also chat to Kevin about his surprising Mounjaro weight loss journey.
Contact
investigatingozempic@gmail.com
Special Note
In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECT of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care profe ...